A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO

Evaluation of the Safety and Efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis: A Prospective, Multicenter, Randomized, Controlled Clinical Study

To evaluate the safety and efficacy of Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) compared with the Balloon Dilatation catheter (OHICHO II) for the treatment of Arteriovenous Fistulae Stenosis in patients undergoing hemodialysis.

To evaluate the safety and efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) compared with the Balloon Dilatation catheter (OHICHO II) for the treatment of Arteriovenous Fistulae Stenosis in patients undergoing hemodialysis.

This is a prospective, multi-center, randomized controlled, open-label, superiority study. A total of 160 subjects will be enrolled from 10 sites in China. All subjects enrolled will be randomly assigned to the test group (APERTO group, n=80) and the control group (OHICHO II group, n=80) with randomized allocation ratio of 1:1. Subjects in the test group and the control group will be treated with APERTO OTW or OHICHO II respectively.

Inclusion criteria:

Patients must meet all of the following criteria:

• Age ≥ 18 years and ≤ 75 years, male or female.

• Patient or legally authorized representative can understand the purpose of this clinic trial. He or She volunteers to participate in this trial and can provide written informed consent, and is willing to accept the scheduled follow-up in specific time points.

• Angiography, ultrasound or clinical diagnosis shows that patients have hemodialysis access dysfunction due to stenosis lesions.

• Patients with indications of the percutaneous endovascular therapy, that is, the AVF stenosis is related to hemodynamics and ≥ 50%, and with any of the following clinical and physiological abnormalities (referred to NKF-K/DOQI guideline definitions):

  1. Thrombosis in the AVF;
  2. Elevated venous pressure during dialysis
  3. Obvious abnormality in recirculation measurements
  4. Abnormal physical examination findings
  5. Unexplained decreases in dialysis dose
  6. Decreased access flow

• Target lesion is a de novo or restenosis. The number of target lesions is 1.

• Target lesion consists of a single lesion or a multiple lesions with target lesion length ≤ 40 mm.

• Target lesion(s) is located in the reflux vein which is from the anastomosis of native arteriovenous fistula (AVF) to the distal end of subclavian vein, except the anastomosis of native AVF.

• If patient has non-target lesion, it must be successfully treated using PTA before treating target lesion.

• Reference vessel diameter of target lesion ≥ 4.0 mm and ≤ 7.0 mm by visual estimate (determined by angiography or DUS).

• Hemodialysis access previously used (mature AVF) can no longer be successfully used due to insufficient shunt flow volume caused by local lumen stenosis.

Exclusion criteria:

Patients will be excluded if any of the following conditions applies:

• Patients who have participated in another investigational drug or device trial.
• Patients who have been enrolled in this trial previously.
• Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women.
• Any major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days prior to the procedure.
• Any planned major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days of entry into this study
• Immature AVF, which cannot be used for Dialysis or has not been used successfully due to insufficient lumen diameter to ensure successfully puncture and insufficient shunt flow volume.
• Patients with AVG.
• AVF has been previously implanted with stent.
• Lesion in AVF has been previously treated with DEB.
• Target lesion is located in the anastomosis of native AVF.
• Known allergies or intolerance to Paclitaxel or contrast medium.
• Life expectancy < 1 year
• Patients with comitans systemic lupus erythematosus and ANCA associated vasculitis.